CN101977628A - α7烟碱激动剂和抗精神病药的组合 - Google Patents

α7烟碱激动剂和抗精神病药的组合 Download PDF

Info

Publication number
CN101977628A
CN101977628A CN2009801102033A CN200980110203A CN101977628A CN 101977628 A CN101977628 A CN 101977628A CN 2009801102033 A CN2009801102033 A CN 2009801102033A CN 200980110203 A CN200980110203 A CN 200980110203A CN 101977628 A CN101977628 A CN 101977628A
Authority
CN
China
Prior art keywords
methyl
azabicyclo
oct
pyridine radicals
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801102033A
Other languages
English (en)
Chinese (zh)
Inventor
M·本切里夫
G·J·加托
T·豪瑟
K·G·乔丹
S·R·莱特克沃斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gyre Therapeutics Inc
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of CN101977628A publication Critical patent/CN101977628A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN2009801102033A 2008-02-13 2009-02-13 α7烟碱激动剂和抗精神病药的组合 Pending CN101977628A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2828208P 2008-02-13 2008-02-13
US61/028,282 2008-02-13
PCT/US2009/034062 WO2009102962A2 (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2013100500436A Division CN103143023A (zh) 2008-02-13 2009-02-13 α7烟碱激动剂和抗精神病药的组合

Publications (1)

Publication Number Publication Date
CN101977628A true CN101977628A (zh) 2011-02-16

Family

ID=40902222

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801102033A Pending CN101977628A (zh) 2008-02-13 2009-02-13 α7烟碱激动剂和抗精神病药的组合
CN2013100500436A Pending CN103143023A (zh) 2008-02-13 2009-02-13 α7烟碱激动剂和抗精神病药的组合

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2013100500436A Pending CN103143023A (zh) 2008-02-13 2009-02-13 α7烟碱激动剂和抗精神病药的组合

Country Status (25)

Country Link
US (1) US20110059947A1 (enExample)
EP (2) EP2254598B1 (enExample)
JP (1) JP2011511845A (enExample)
KR (1) KR20100113163A (enExample)
CN (2) CN101977628A (enExample)
AU (1) AU2009214625A1 (enExample)
BR (1) BRPI0907570A2 (enExample)
CA (1) CA2715268A1 (enExample)
CO (1) CO6290706A2 (enExample)
CY (1) CY1114492T1 (enExample)
DK (1) DK2254598T3 (enExample)
EC (1) ECSP10010471A (enExample)
ES (1) ES2430622T3 (enExample)
HR (1) HRP20130749T1 (enExample)
IL (1) IL207389A0 (enExample)
MX (1) MX2010008875A (enExample)
NZ (1) NZ587312A (enExample)
PL (1) PL2254598T3 (enExample)
PT (1) PT2254598E (enExample)
RS (1) RS52941B (enExample)
RU (1) RU2481123C2 (enExample)
SG (1) SG188144A1 (enExample)
SI (1) SI2254598T1 (enExample)
WO (1) WO2009102962A2 (enExample)
ZA (1) ZA201005999B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
CN108727416A (zh) * 2017-04-20 2018-11-02 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
BR122014023207A2 (pt) 2010-09-23 2019-05-28 Abbvie Inc. Compostos derivados de aza-adamantano, seus usos e processos para a preparação destes compostos
PH12013501509A1 (en) * 2011-01-18 2019-08-07 Targacept Inc Treatment of cognitive dysfunction in schizophrenia
WO2012151136A1 (en) * 2011-05-03 2012-11-08 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
US20150259344A1 (en) * 2012-10-02 2015-09-17 Dainippon Sumitomo Pharma Co., Ltd. Imidazole derivative
JP6807094B2 (ja) * 2016-04-29 2021-01-06 国立大学法人秋田大学 クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法
EP3338768B1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
WO2022150560A1 (en) * 2021-01-08 2022-07-14 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
JP2024502474A (ja) 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
DE102022114269A1 (de) 2022-06-07 2023-12-07 Rational Aktiengesellschaft Gargerät mit einem Selbstreinigungssystem sowie ein Verfahren zum Ändern von Reinigungsparametern für das Gargerät

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5712270A (en) * 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
PT1083889E (pt) 1998-06-01 2004-04-30 Ortho Mcneil Pharm Inc Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
WO2001041750A2 (en) * 1999-12-10 2001-06-14 Wyeth Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics
SI1300407T2 (sl) * 2000-06-27 2011-09-30 S A L V A T Lab Sa Karbamati, izvedeni iz arilalkilaminov
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
JP2004506734A (ja) 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
US6554086B1 (en) * 2000-10-27 2003-04-29 Invacare Corporation Obstacle traversing wheelchair
JP4445704B2 (ja) 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
MXPA04008152A (es) * 2002-02-19 2005-09-08 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
EP1572700A1 (en) * 2002-12-06 2005-09-14 Pharmacia & Upjohn Company LLC Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
BRPI0418092A (pt) * 2003-12-23 2007-04-17 Pfizer Prod Inc combinação terapêutica para melhora cognitiva e transtornos psicóticos
JP2008533142A (ja) * 2005-03-18 2008-08-21 アボット・ラボラトリーズ α７ニューロンニコチン性受容体リガンドおよび抗精神病薬組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108727416A (zh) * 2017-04-20 2018-11-02 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途
CN108727416B (zh) * 2017-04-20 2021-03-09 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂

Also Published As

Publication number Publication date
SG188144A1 (en) 2013-03-28
RU2481123C2 (ru) 2013-05-10
ECSP10010471A (es) 2010-10-30
WO2009102962A3 (en) 2009-10-08
EP2254598A2 (en) 2010-12-01
RS52941B (sr) 2014-02-28
MX2010008875A (es) 2010-08-31
HK1147954A1 (en) 2011-08-26
KR20100113163A (ko) 2010-10-20
US20110059947A1 (en) 2011-03-10
CA2715268A1 (en) 2009-08-20
DK2254598T3 (da) 2013-07-29
PT2254598E (pt) 2013-10-16
ES2430622T3 (es) 2013-11-21
BRPI0907570A2 (pt) 2019-09-24
IL207389A0 (en) 2010-12-30
CN103143023A (zh) 2013-06-12
CO6290706A2 (es) 2011-06-20
HRP20130749T1 (en) 2013-10-11
PL2254598T3 (pl) 2013-12-31
EP2633868A1 (en) 2013-09-04
ZA201005999B (en) 2011-05-25
WO2009102962A2 (en) 2009-08-20
NZ587312A (en) 2011-12-22
SI2254598T1 (sl) 2013-10-30
JP2011511845A (ja) 2011-04-14
AU2009214625A1 (en) 2009-08-20
EP2254598B1 (en) 2013-07-10
CY1114492T1 (el) 2016-10-05
RU2010137787A (ru) 2012-03-20

Similar Documents

Publication Publication Date Title
CN101977628A (zh) α7烟碱激动剂和抗精神病药的组合
Dwomoh et al. Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
JP7082186B2 (ja) プリドピジンによる筋萎縮性側索硬化症の治療方法
US20100178277A1 (en) Methods and compositions for stimulating cells
US20220202798A1 (en) Use of pridopidine for the treatment of fragile x syndrome
EP3606525B1 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
US20070293538A1 (en) Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
AU2021200697A1 (en) Use of pridopidine for the treatment of anxiety and depression
WO2009135091A1 (en) Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
JP2018520187A (ja) 神経変性疾患と関連する幻覚の予防および処置のために有用な５−ｈｔ２ａセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体
KR20190124722A (ko) 신경계 장애의 치료에서 사용하기 위한 ｄ-메타돈 및 이의 유도체
WO2021016369A1 (en) Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
JP2009534415A (ja) ニューロトロフィン発現に対するａｍｐａ受容体モジュレーターの作用の薬理学的制御
JP2022511266A (ja) 陰性症状および障害を処置するため、神経可塑性を増大するため、ならびに神経保護を促進するためのロルペリドンの使用
Lippiello et al. Nicotinic receptors as targets for therapeutic discovery
HK1185794A (en) Combination of alpha 7 nicotinic agonists and antipsychotics
HK1147954B (en) Combination of alpha 7 nicotinic agonists and antipsychotics
JP7650270B2 (ja) 併用療法を用いた統合失調症性障害の治療
JP5714572B2 (ja) 精神障害およびその症状の治療のためのｋｃｎｑカリウムチャネル活性の調節方法
Hori Developmental Effects of Bilateral Ventral Hippocampal Lesions on Neocortical [capital Delta] FosB Expression and Cognition: Reversal of Cognitive Deficits by Darbepoetin Alfa But Not Clozapine
Goff et al. Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110216